- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03134521
Population Pharmacokinetic Analysis of Daptomycin in Patients With Osteoarticular Infections
Daptomycin is validated as a treatment of bone and joint infections by the Infectious Disease Society of America. However, most of studies did not investigate daptomycin pharmacokinetics in this indication while it is known that efficacy and toxicity concentration studies show a close therapeutic margin.
Evaluation of P-Glycoprotein (P-gp), a transmembrane transport protein, has demonstrated its influence on the concentration and intracellular activity of daptomycin. Recent work has linked the genetic polymorphism of P-gp to the pharmacokinetics of daptomycin, which may explain inter-individual variability but requires further explorations. Previous studies demonstrated existence of interindividual variabilities as sex, renal function and p-glycoprotein polymorphism couple with an intraindividual variabilities unexplained yet.
A population approach will be used to determinate the pharmacokinetics factors, their intra and interindividual variabilities, the parameters associated to those variabilities (as the p glycoprotein).
The investigator's goal is to evaluate different posology and to try to increase daptomycin efficacy and security in bone and joint infection.
Studieoversikt
Status
Forhold
Studietype
Registrering (Faktiske)
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
Patients
- having had a bone or joint infection, with or without implant,
- having an antibiotherapy with daptomycin between December 2012 and December 2016 at the Croix-Rousse hospital
- are at least 18 years old
Exclusion Criteria:
- None
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Peak plasma concentration (Cmax)
Tidsramme: Month 6
|
Month 6
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Area under the concentration-time curve
Tidsramme: up to 6 months
|
up to 6 months
|
|
typical daptomycin clearance and volume of distribution in the population
Tidsramme: Month 6
|
Month 6
|
|
Mean daptomycine plasma clearance
Tidsramme: Month 6
|
(unit, liters per hour)
|
Month 6
|
Mean daptomycine volume of distribution
Tidsramme: Month 6
|
(unit, liters)
|
Month 6
|
Inter-individual coefficient of variation of daptomycin clearance
Tidsramme: Month 6
|
(unit, %)
|
Month 6
|
Inter-individual coefficient of variation of daptomycin volume of distribution
Tidsramme: Month 6
|
(unit, %)
|
Month 6
|
Intra-individual coefficient of variation of daptomycin clearance
Tidsramme: Month 6
|
(unit, %)
|
Month 6
|
Intra-individual coefficient of variation of daptomycin volume of distribution
Tidsramme: Month 6
|
(unit, %)
|
Month 6
|
influence of demographic and biological covariates on pharmacokinetics (e.g. : renal function, gender)
Tidsramme: Month 6
|
the influence of demographic and biological covariates on pharmacokinetics will be assessed statistically by using the Akaike Information Criterion (AIC, no unit).
AIC = -2xLL + 2P, where LL is the log-likelihood computed by the population algorithm and P is the number of parameters in the model.
A covariate will be considered as significant if it is associated with a decrease in the AIC value compared with the base model without covariate.
|
Month 6
|
influence of p-glycoprotein pharmacogenetics on daptomycin pharmacokinetics
Tidsramme: Month 6
|
the influence of P-glycoprotein pharmacogenetics on pharmacokinetics will be assessed statistically by using the Akaike Information Criterion (AIC, no unit).
AIC = -2xLL + 2P, where LL is the log-likelihood computed by the population algorithm and P is the number of parameters in the model.
The P-glycoprotein genotype will be considered as significant if it is associated with a decrease in the AIC value compared with the base model without covariate.
|
Month 6
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Tristan Ferry, Hospices Civils de Lyon - Hopital de la Croix Rousse
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 69HCL17_0182
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Beininfeksjon
-
Universidad del DesarrolloFullførtHealthcare Associated InfectionChile
-
Imelda Hospital, BonheidenFullførtHealthcare Associated InfectionBelgia
-
Centre Hospitalier Universitaire de NīmesRekrutteringEldre | Healthcare Associated InfectionFrankrike
-
Centre Hospitalier Universitaire, AmiensFullførtHealthcare Associated Infection | IglerFrankrike
-
University of PennsylvaniaFullførtAntimikrobiell resistensForente stater, Botswana
-
University of Maryland, BaltimoreVA Office of Research and DevelopmentFullførtMenneskelig mikrobiomForente stater
-
Universidad Autonoma de Nuevo LeonUkjentHelsetilknyttede infeksjoner
-
Johns Hopkins UniversityFullførtHealthcare Associated Infection | Multiresistente organismer
-
University of Colorado, DenverUniversity of IowaFullførtHealth Care Associated Infection | HåndhygieneForente stater
-
Aionx, Inc.UkjentHealthcare Associated Infection